Presepsin Values Evaluated as Sepsis Severity Markers
|
By LabMedica International staff writers Posted on 23 Jun 2020 |

Image: Presepsin concentrations (ng/mL) in two severity groups. Black line: sepsis patients; black dotted line: septic shock patients (Photo courtesy of University Hospital for Infectious Diseases in Zagreb).
Sepsis is a life-threatening condition, with poor and highly variable clinical manifestations, difficult to identify and diagnose. Sepsis has remained a real diagnostic challenge to clinicians, causing millions of death worldwide each year. Early recognition of sepsis is crucial for better disease outcome.
Blood cultures are a gold standard for diagnosing sepsis. Despite the great advantages, blood cultures also have some limitations as they are often negative, especially in patients previously treated with antibiotic, and their results are usually obtained over several days. While waiting for blood culture results, treatment of critically ill septic patients may be delayed, increasing the possibility of poor outcome.
Infectious disease specialist at the University Hospital for Infectious Diseases (Zagreb, Croatia) and their colleagues conducted a prospective observational study in two university clinical centers and enrolled 100 septic patients during two time periods. New Sepsis-3 definitions were used for sepsis stratification. Biomarkers and SOFA score were evaluated four times during the illness.
Routine laboratory parameters and C-reactive protein (CRP) were tested immediately. For procalcitonin (PCT) and presepsin levels measurements, blood was collected at all four time points, frozen until the end of the study, and then measured. Quantitative analysis of PCT was performed using an automated electrochemiluminescence immunoanalyzer (ELECSYS* BRAHMS* PCT; Roche Diagnostics, Mannheim, Germany). A sandwich enzyme-linked immune-sorbent assay ̶ Human Presepsin ELISA Kit (Nordic Biosite, Täby, Sweden), was used for presepsin measurement.
The following laboratory parameters were recorded: red blood cell count, hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, serum total bilirubin, serum liver enzymes (aspartate aminotransferase-AST and alanine aminotransferase-ALT), partial thromboplastin time (PTT), international normalized ratio (INR), electrolytes (sodium and potassium), blood gas analysis, CRP, PCT, and presepsin concentrations.
The scientists reported that presepsin concentrations were significantly higher on admission in 34 patients with septic shock compared to 66 patients with sepsis, mean ± SD: 128.5 ± 47.6 ng/mL versus 88.6 ± 65.6 ng/mL, respectively. The same was not observed for PCT and CRP; their concentrations did not differ significantly between severity groups. A strong correlation of presepsin with SOFA score was also found.
The authors concluded that their study showed that serum presepsin concentration on admission reflects the severity of disease. Presepsin was a better predictor of multiple organ dysfunction syndrome compared to other tested sepsis biomarkers. The strong correlation of presepsin with SOFA score makes this marker a valuable tool for identifying septic patients. PCT and CRP concentrations did not differ between sepsis severity groups. The study was published in the June, 2020 issue of the International Journal of Infectious Diseases.
Blood cultures are a gold standard for diagnosing sepsis. Despite the great advantages, blood cultures also have some limitations as they are often negative, especially in patients previously treated with antibiotic, and their results are usually obtained over several days. While waiting for blood culture results, treatment of critically ill septic patients may be delayed, increasing the possibility of poor outcome.
Infectious disease specialist at the University Hospital for Infectious Diseases (Zagreb, Croatia) and their colleagues conducted a prospective observational study in two university clinical centers and enrolled 100 septic patients during two time periods. New Sepsis-3 definitions were used for sepsis stratification. Biomarkers and SOFA score were evaluated four times during the illness.
Routine laboratory parameters and C-reactive protein (CRP) were tested immediately. For procalcitonin (PCT) and presepsin levels measurements, blood was collected at all four time points, frozen until the end of the study, and then measured. Quantitative analysis of PCT was performed using an automated electrochemiluminescence immunoanalyzer (ELECSYS* BRAHMS* PCT; Roche Diagnostics, Mannheim, Germany). A sandwich enzyme-linked immune-sorbent assay ̶ Human Presepsin ELISA Kit (Nordic Biosite, Täby, Sweden), was used for presepsin measurement.
The following laboratory parameters were recorded: red blood cell count, hemoglobin, hematocrit, white blood cell count, platelet count, serum creatinine, serum total bilirubin, serum liver enzymes (aspartate aminotransferase-AST and alanine aminotransferase-ALT), partial thromboplastin time (PTT), international normalized ratio (INR), electrolytes (sodium and potassium), blood gas analysis, CRP, PCT, and presepsin concentrations.
The scientists reported that presepsin concentrations were significantly higher on admission in 34 patients with septic shock compared to 66 patients with sepsis, mean ± SD: 128.5 ± 47.6 ng/mL versus 88.6 ± 65.6 ng/mL, respectively. The same was not observed for PCT and CRP; their concentrations did not differ significantly between severity groups. A strong correlation of presepsin with SOFA score was also found.
The authors concluded that their study showed that serum presepsin concentration on admission reflects the severity of disease. Presepsin was a better predictor of multiple organ dysfunction syndrome compared to other tested sepsis biomarkers. The strong correlation of presepsin with SOFA score makes this marker a valuable tool for identifying septic patients. PCT and CRP concentrations did not differ between sepsis severity groups. The study was published in the June, 2020 issue of the International Journal of Infectious Diseases.
Latest Clinical Chem. News
- Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
- Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
- Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
- Global Survey Underscores Need to Standardize Bone Biomarker Testing
- Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
- Noninvasive Earwax Test Aims to Detect Meniere’s Disease
- Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
- Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
- First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
- Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
- Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
- Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
Channels
Molecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







